HC Wainwright Initiates Coverage on Fractyl Health (NASDAQ:GUTS)

Key Points

• HC Wainwright has initiated coverage on Fractyl Health (NASDAQ:GUTS) with a "buy" rating and a target price of $9.00.
• Fractyl Health has recently faced challenges, reporting an EPS of ($0.53), missing estimates and exhibiting a negative return on equity of 584.35%.
• Multiple institutional investors, including Osaic Holdings and General Catalyst Group, have increased their stakes significantly in Fractyl Health, reflecting growing interest in the company.

Stock analysts at HC Wainwright assumed coverage on shares of Fractyl Health (NASDAQ:GUTS - Get Free Report) in a research report issued on Monday,Benzinga reports. The firm set a "buy" rating and a $9.00 price target on the stock.

A number of other equities analysts have also recently issued reports on GUTS. LADENBURG THALM/SH SH began coverage on shares of Fractyl Health in a report on Thursday, August 28th. They issued a "buy" rating and a $3.60 target price on the stock. Canaccord Genuity Group cut their target price on shares of Fractyl Health from $12.00 to $6.00 and set a "buy" rating on the stock in a report on Thursday, August 14th. Four investment analysts have rated the stock with a Buy rating, According to MarketBeat.com, the stock has an average rating of "Buy" and a consensus target price of $7.15.

Fractyl Health Stock Performance

Shares of GUTS stock opened at $1.02 on Monday. The company has a debt-to-equity ratio of 4.61, a quick ratio of 1.22 and a current ratio of 1.22. Fractyl Health has a one year low of $0.83 and a one year high of $3.48. The company's 50-day simple moving average is $1.32 and its 200-day simple moving average is $1.46. The stock has a market capitalization of $51.30 million, a price-to-earnings ratio of -0.50 and a beta of 1.58.

Fractyl Health (NASDAQ:GUTS - Get Free Report) last issued its quarterly earnings results on Tuesday, August 12th. The company reported ($0.53) EPS for the quarter, missing the consensus estimate of ($0.37) by ($0.16). Fractyl Health had a negative return on equity of 584.35% and a negative net margin of 73,864.52%. Equities analysts anticipate that Fractyl Health will post -1.61 earnings per share for the current fiscal year.

Institutional Inflows and Outflows

Several hedge funds have recently added to or reduced their stakes in the business. Osaic Holdings Inc. grew its position in Fractyl Health by 460.3% in the second quarter. Osaic Holdings Inc. now owns 59,645 shares of the company's stock worth $97,000 after buying an additional 49,000 shares during the last quarter. Jane Street Group LLC acquired a new position in Fractyl Health in the second quarter worth approximately $31,000. General Catalyst Group Management LLC purchased a new position in Fractyl Health during the 2nd quarter worth approximately $7,912,000. Qube Research & Technologies Ltd purchased a new position in Fractyl Health during the 2nd quarter worth approximately $129,000. Finally, Catalyst Funds Management Pty Ltd purchased a new position in Fractyl Health during the 2nd quarter worth approximately $26,000.

Fractyl Health Company Profile

Fractyl Health, Inc, a metabolic therapeutics company, develops therapies for the treatment of type 2 diabetes (T2D) and obesity. The company develops Revita DMR System (Revita), an outpatient procedural therapy designed to durably modify duodenal dysfunction, a pathologic consequence of a high fat and high sugar diet, which can initiate T2D and obesity in humans.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.